Maryland Awards $1.4 Million in Biotech Grants
Tip: Highlight text to annotate itX
>> I THINK WHAT WE'RE DOING
TODAY IS RECOGNIZING SEVEN
COMPANIES WHO HAVE GONE THROUGH
A COMPETITIVE PROCESS TO
BASICALLY RECEIVE THE
BIOTECHNOLOGY DEVELOPMENT AWARDS
THAT FALL INTO TWO CATEGORIES OF
EITHER TRANSLATIONAL RESEARCH OR
COMMERCIALIZATION.
>> WE HAVE A TRANSLATIONAL
ONCOLOGY COMPOUND WHICH WE
BELIEVE VERY EFFECTIVELY ATTACKS
CANCER CELLS INTO A REAL STEM
CELL-LIKE STATE.
AND THIS IS THOUGHT TO BE ONE OF
THE MAIN MECHANISMS BY WHICH
CANCER AVOIDS BEING KILLED BY
CHEMOTHERAPY.
>> THIS CRITICAL FUNDING COMES
FROM THE MARYLAND BITECH CENTER
AND THE STATE OF MARYLAND IS
GOING TO HELP US BRING A LEAD
PRODUCT THAT WE HAVE THAT IS A
LONG-LASTING THERAPY THAT TREATS
THE DISEASE AGE-RELATED MACULAR
DEGENERATION TOWARDS THE HUMAN
CLINICAL TRIALS THAT WE HOPE
WILL HAPPEN IN THE NEXT ONE TO
TWO YEARS.
>> I FIND THE USES OF WORKING IN
THE MARYLAND BIOTECHNOLOGY
CENTER IS THE SALE OF PRODUCTION
OF OUR FIRST THERAPEUTIC CALLED
FC-DIMERS AND TO USE IT IN A
SMALL AND MURINE MODEL OF
MULTIPLE SCLEROSIS CALLED
EXPERIMENTAL AUTOIMMUNE
ENCEPHALOMYELITIS.
WE EXPECT TO GO FROM THERE
RAPIDLY TO PHASE ONE CLINICAL
HUMAN TRIALS HERE IN THE STATE
OF MARYLAND.
>> I FIRMLY BELIEVE WE WANT TO
REVOLUTIONALIZE THE [indistinct]
INDUSTRY.
OUR COMPETITOR JUST PUT OUT A
PRESS RELEASE THAT THEY HAVE A
TEST THAT WILL TURN AROUND
RESULTS IN 27 HOURS.
WE CAN DO THE SAME THING IN A
COUPLE OF MINUTES SO--
>> SANARIA, AS MANY OF YOU MAY
KNOW, IS THE ONLY COMPANY IN THE
WORLD ENTIRELY DEDICATED TO
MALARIA VACCINE DEVELOPMENT, AND
WE'VE BEEN DOING EXTREMELY WELL
AND IN EITHER ONGOING OR IN THE
NEXT YEAR, WE'RE GOING TO HAVE
14 CLINICAL TRIALS IN EIGHT
COUNTRIES ON THREE CONTINENTS OF
OUR MALARIA PRODUCTS.
>> OUR NANOCHEMISTY CRYSTAL
TECHNOLOGY IS VERY
COST-EFFECTIVE, PROPRIETARY, AND
VERY POWERFUL.
YOU CAN DO MOLECULAR DIAGNOSTICS
AND IMMUNOASSAY IN A WIDE
VARIETY OF FORMATS.
>> THERE'S A LOT OF ACADEMIC
DATA AROUND THIS CONCEPT OF
ARTIFICIAL CELLS WHICH WE'VE NOW
TAKEN IT ON AS A COMPANY TO
ACTUALLY MOVE THIS TO A POINT
WHERE WE CAN ACTUALLY MAKE ONE
OF THESE CELLS TO TEST ON HUMANS
AND THIS GRANT IS REALLY GOING
TO HELP US MAKE THAT TRANSITION
FROM ACADEMIA TO SORT OF OKAY,
HERE IS A PRODUCT THAT WILL
BENEFIT--
